Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Amedisys initiation details — Hold at The Benchmark Company; tgt $50 (47.60)The Benchmark Company initiates AMED with a Hold and price target of $50. As the leading scale player in home health, AMED is positioned to benefit from emerging healthcare delivery trends. In a nutshell, financial incentives are increasingly focused on low cost/high quality care — and home health is often the most viable post-acute alternative. Competitive advantages for AMED include its heavy concentration in CON states; a strong focus on achieving operational benchmarks that will support higher sustainable growth and profitability; an enhanced and incentivized senior management team and a healthy financial condition to support continued M&A.</td> </tr></table>"